Bli medlem
Bli medlem

Du är här


Coegin Pharma AB: BioStock: Coegin Pharma receives final approval for COAK Study

After complying with the conditions given by the Danish Ethics committee in September, Nordic biotech Coegin Pharma has received the final approval for initiating the phase I/II COAK study in actinic keratosis patients. From the beginning of November, the company will begin patient recruitment, and thus take an important step towards developing a novel treatment for a disease with a large unmet medical need.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision